Similarly, several studies show that disrupting PI3K/Akt pathway activity in colorectal cancer enhances treatment efficacy with GPX4 inhibitors like RSL3 plus sorafenib (Chen H. et al., 2022; Wang L. et al., 2023). Here, PIK3CA is linked to colorectal cancer.